Protagonist Therapeutics Inc. (PTGX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Protagonist Therapeutics Inc. (PTGX:NASDAQ), powered by AI.

Current Price
$133.00
P/E Ratio
-65.0
Market Cap
8.5B
Sector
Healthcare
What is the Protagonist Therapeutics Inc. stock price forecast?

Protagonist Therapeutics Inc. is currently trading at $133.00. View real-time AI analysis on Alpha Lenz.

What is Protagonist Therapeutics Inc. insider trading activity?

View the latest insider trading data for Protagonist Therapeutics Inc. on Alpha Lenz.

What is Protagonist Therapeutics Inc.'s P/E ratio?

Protagonist Therapeutics Inc.'s P/E ratio is -65.0.

Protagonist Therapeutics Inc.

NASDAQ · PTGX
$133.00-3.84(-2.81%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Protagonist Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Protagonist Therapeutics Inc. trades at a P/E of -65.0 (undervalued) with modest ROE of -20.2%. 3Y revenue CAGR of 20.1% highlights clear growth momentum.

Ask for details

Company Overview

Protagonist Therapeutics Inc. is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. These therapeutics are designed to address significant unmet medical needs, focusing on diseases that involve critical biological pathways regulated by peptides and proteins. Utilizing a proprietary technology platform, Protagonist Therapeutics develops solutions for conditions such as inflammatory bowel disease, myeloproliferative neoplasms, and other serious health disorders. The company’s innovative approach aims to combine the efficacy and safety of peptide drugs with novel mechanisms of action, providing targeted treatments that can potentially improve patient outcomes. Located in Newark, California, Protagonist Therapeutics plays a vital role in the biotechnology industry, contributing to advances in medical treatments and the broader healthcare sector. Its research and development efforts are significant, offering potential new therapies that could positively impact both patients’ lives and healthcare practices.

CEODr. Dinesh V. Patel Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees130

Company Statistics

FY 2025

Profile

$8.46BMarket Cap
$46.02MRevenue
0.00Shares Out
130Employees

Margins

N/AGross
-340.85%EBITDA
-343.63%Operating
-281.01%Pre-Tax
-282.83%Net

Valuation

-64.97P/E
13.75P/B
183.75EV/Sales
-53.15EV/EBITDA
150.77P/FCF

Growth (CAGR)

20.07%Rev 3Yr
9.96%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-18.42%ROA
-20.18%ROE
-22.38%ROIC

Financial Health

$128.39MCash & Cash Equivalents
$-74.91MNet Debt
8.70%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Protagonist Therapeutics Inc. (ticker: PTGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $8.5B.

The current price is $133 with a P/E ratio of -64.97x and P/B of 13.75x.

ROE is -20.18% and operating margin is -343.63%. Annual revenue is $46M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Protagonist Therapeutics Inc. (PTGX) Stock Forecast 2026 $133.00 — Price, Financials & Analyst Targets | Alpha Lenz